Drug intelligence / Profile preview

cefdinir + clavulanic acid

Development stage: Unknown
Lead developer: Neutec
Modality: Small Molecules
Administration: Oral

Overview

Cefdinir + clavulanic acid is an oral combination antibiotic product composed of cefdinir, a third-generation cephalosporin, and clavulanic acid, a beta-lactamase inhibitor. Cefdinir inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell death. Clavulanic acid irreversibly inhibits a range of beta-lactamase enzymes, which protects cefdinir from degradation by resistant bacteria and extends its antibacterial spectrum. This combination is primarily indicated for the treatment of respiratory tract infections due to susceptible bacteria.

Brand names: FULLCEF PLUS
Other names: Clavulanic Acid/Cefdinir film coated tablets

Targets

PBP2 (Penicillin-binding protein 2)β-lactamase

Beyond the preview

Go deeper on cefdinir + clavulanic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cefdinir + clavulanic acid.

Explore the full profile